DARE Daré Bioscience, Inc.
USHealthcareAs of 2026-07-10 16:00
Why DARE matters now
Daré Bioscience, Inc. (DARE) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.02 with -2.42% on the session and $19.2M in market capitalization; recent performance reads 1-month -3.56% and YTD +12.44%.
The latest financial table shown here is Q1 2026, with revenue of $152.5K, net income of $-3.0M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -49.2%.
The latest indexable market news headline is "Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Grossman Jessica D. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
42.91
P/S
17.85
EV/EBITDA
-0.39
DCF Value
$0.18
FCF Yield
-49.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
5.6%
Operating Margin
-1034.4%
Net Margin
-1038.8%
ROE
763.4%
ROA
-43.2%
ROIC
-151.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $152.5K | $-3.0M | $-0.21 |
| Q4 2025 | $1.0M | $-1.4M | $-0.10 |
| FY 2025 | $1.0M | $-13.4M | $-1.20 |
| Q3 2025 | $2.3K | $-3.6M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.02
Daré Bioscience, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market healthcare solutions specifically for women in the United States. Its comprehensive pipeline addresses a broad spectrum of needs within women's health, encompassing contraception, fertility, and both sexual and vaginal well-being. The company's initial commercial offering is XACIATO, a prescription single-dose vaginal gel designed to treat bacterial vaginosis in female patients from 12 years of age. Daré has established a licensing agreement with Organon & Co. and Organon International GmbH to commercialize this product. Beyond its marketed therapy, Daré boasts a robust development portfolio. In advanced clinical stages, it is progressing Ovaprene, a monthly hormone-free vaginal contraceptive, and Sildenafil Cream, a topical formulation of sildenafil intended for vulvar and vaginal application to manage female sexual arousal disorder. Several programs are primed for Phase 1 clinical trials, including DARE-HRT1, an intravaginal ring delivering a combination of bio-identical estradiol and progesterone for vasomotor symptom management in hormone therapy. Also in this category are DARE-VVA1, a vaginally administered tamoxifen formulation targeting vulvar and vaginal atrophy in patients with hormone-receptor-positive breast cancer; DARE-FRT1, an intravaginal ring containing bio-identical progesterone for both preterm birth prevention and broader luteal phase support during in vitro fertilization; and DARE-PTB1, another intravaginal ring also utilizing bio-identical progesterone for preventing preterm birth. At the pre-clinical level, Daré is exploring innovative solutions such as DARE-LARC1, a combination product aimed at reversible contraception. This stage also includes ADARE-204 and ADARE-214, which are injectable etonogestrel formulations intended to provide contraception for 6-month and 12-month periods, respectively, alongside DARE-RH1, a non-hormonal contraceptive approach for both men and women. Daré Bioscience, Inc. maintains its corporate headquarters in San Diego, California.